代谢综合征与肺腺癌患者临床分期的相关性研究

目的:探讨代谢综合征（metabolic syndrome,MS）与肺腺癌临床分期的相关性。方法:2018年1月至2019年1月由华北理工大学附属医院首次确诊为肺腺癌的患者135例。57例被诊断为代谢综合征合并肺腺癌患者纳入病例组,78例为单纯肺腺癌患者纳入对照组。收集病例人口学信息、首次生化检查结果、临床症状及肺腺癌临床分期,SPSS 23.0用于数据分析。结果:经多元Logistic回归分析发现MS并不会导致肺腺癌临床症状的改变（P均大于0.05）,但是却与肺腺癌患者的临床分期相关（P=0.019）,与单纯肺腺癌患者相比,MS合并肺腺癌的患者肿瘤临床分期为晚期的概率上升了51.8%。结论:MS与肺腺癌患者的肿瘤临床分期存在相关性,MS可能是导致肺腺癌临床分期严重程度的独立危险因素。

Correlation between metabolic syndrome and clinical stage of patients with lung adenocarcinoma

Objective:To investigate the relationship between metabolic syndrome (MS) and clinical stage of lung adenocarcinoma.Methods:From January 2018 to January 2019,135 patients with lung adenocarcinoma were first diagnosed by the Affiliated Hospital of North China University of Technology.Fifty-seven patients with metabolic syndrome and lung adenocarcinoma were enrolled in the case group,and 78 patients with simple lung adenocarcinoma were included in the control group.Case demographic information,first biochemical examination results,clinical symptoms and clinical stage of lung adenocarcinoma were collected,and SPSS 23.0 was used for data analysis.Results:Multivariate logistic regression analysis showed that MS did not cause changes in the clinical symptoms of lung adenocarcinoma (P＞0.05),but was associated with clinical stage of lung adenocarcinoma patients (P=0.019).Compared with patients with simple lung adenocarcinoma.The probability of advanced clinical stage of tumors in patients with MS with lung adenocarcinoma increased by 51.8%.Conclusion:MS has a correlation with the clinical stage of tumor in patients with lung adenocarcinoma.MS may be an independent risk factor for the severity of clinical stage of lung adenocarcinoma.